Pieris Pharmaceuticals Inc (NASDAQ:PIRS) – Investment analysts at Oppenheimer Holdings issued their Q1 2018 earnings estimates for shares of Pieris Pharmaceuticals in a research report issued on Thursday. Oppenheimer Holdings analyst H. Singh anticipates that the biotechnology company will post earnings per share of ($0.22) for the quarter. Oppenheimer Holdings has a “Buy” rating and a $9.00 price target on the stock. Oppenheimer Holdings also issued estimates for Pieris Pharmaceuticals’ Q2 2018 earnings at ($0.21) EPS, Q3 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.20) EPS, FY2019 earnings at ($0.88) EPS and FY2020 earnings at ($0.85) EPS.

Separately, TheStreet raised shares of Pieris Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Wednesday, May 3rd.

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

COPYRIGHT VIOLATION NOTICE: “Pieris Pharmaceuticals Inc (PIRS) Expected to Earn Q1 2018 Earnings of ($0.22) Per Share” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/05/15/pieris-pharmaceuticals-inc-pirs-expected-to-earn-q1-2018-earnings-of-0-22-per-share.html.

Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 3.80 on Monday. The firm’s market cap is $163.62 million. The stock has a 50 day moving average price of $2.74 and a 200-day moving average price of $2.08. Pieris Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $4.17.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.16 by $0.35. The company had revenue of $1.34 million during the quarter, compared to analyst estimates of $32.30 million. Pieris Pharmaceuticals had a negative net margin of 364.96% and a negative return on equity of 60.26%.

Several hedge funds have recently added to or reduced their stakes in PIRS. Renaissance Technologies LLC purchased a new stake in Pieris Pharmaceuticals during the first quarter valued at approximately $661,000. Morgan Stanley raised its stake in Pieris Pharmaceuticals by 5.3% in the first quarter. Morgan Stanley now owns 191,917 shares of the biotechnology company’s stock valued at $499,000 after buying an additional 9,733 shares during the last quarter. Sphera Funds Management LTD. raised its stake in Pieris Pharmaceuticals by 23.5% in the first quarter. Sphera Funds Management LTD. now owns 1,000,000 shares of the biotechnology company’s stock valued at $2,600,000 after buying an additional 190,000 shares during the last quarter. Creative Planning raised its stake in Pieris Pharmaceuticals by 29.6% in the first quarter. Creative Planning now owns 60,000 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 13,700 shares during the last quarter. Finally, BVF Inc. IL raised its stake in Pieris Pharmaceuticals by 321.2% in the third quarter. BVF Inc. IL now owns 1,016,593 shares of the biotechnology company’s stock valued at $1,858,000 after buying an additional 775,241 shares during the last quarter. 47.58% of the stock is owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

5 Day Chart for NASDAQ:PIRS

Receive News & Ratings for Pieris Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.